Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePhillip Pymm, Wai‐Hong Tham, Amy Adair et al.|Proceedings of the National Academy of Sciences|2021Cited by 165
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainAdam K. Wheatley, Wai‐Hong Tham, Phillip Pymm et al.|Cell Reports|2021Cited by 80
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Keith J. Chappell, Mylinh La et al.|Clinical & Translational Immunology|2021Cited by 62
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Phillip Pymm, Nicholas A. Gherardin, Samuel J. Redmond et al.|iScience|2022Cited by 19
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Dale I. Godfrey, Nicholas A. Gherardin et al.|EBioMedicine|2023Cited by 17